These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 14755459)

  • 1. Screening adherence in BRCA1/2 families is associated with primary physicians' behavior.
    Tinley ST; Houfek J; Watson P; Wenzel L; Clark MB; Coughlin S; Lynch HT
    Am J Med Genet A; 2004 Feb; 125A(1):5-11. PubMed ID: 14755459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing.
    Botkin JR; Smith KR; Croyle RT; Baty BJ; Wylie JE; Dutson D; Chan A; Hamann HA; Lerman C; McDonald J; Venne V; Ward JH; Lyon E
    Am J Med Genet A; 2003 Apr; 118A(3):201-9. PubMed ID: 12673648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rural physicians' perspectives on cervical and breast cancer screening: a gender-based analysis.
    Ahmad F; Stewart DE; Cameron JI; Hyman I
    J Womens Health Gend Based Med; 2001 Mar; 10(2):201-8. PubMed ID: 11268303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening behavior in women at increased familial risk for breast cancer.
    Antill YC; Reynolds J; Young MA; Kirk JA; Tucker KM; Bogtstra TL; Wong SS; Dudding TE; Di Iulio JL; Phillips KA
    Fam Cancer; 2006; 5(4):359-68. PubMed ID: 16817030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA1/2 testing in hereditary breast and ovarian cancer families III: risk perception and screening.
    McInerney-Leo A; Hadley D; Kase RG; Giambarresi TR; Struewing JP; Biesecker BB
    Am J Med Genet A; 2006 Oct; 140(20):2198-206. PubMed ID: 16969872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast cancer screening in BRCA1 and BRCA2 mutation carriers after risk reducing salpingo-oophorectomy.
    Fakkert IE; Jansen L; Meijer K; Kok T; Oosterwijk JC; Mourits MJ; de Bock GH
    Breast Cancer Res Treat; 2011 Aug; 129(1):157-64. PubMed ID: 21373873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are physician recommendations for BRCA1/2 testing in patients with breast cancer appropriate? A population-based study.
    McCarthy AM; Bristol M; Fredricks T; Wilkins L; Roelfsema I; Liao K; Shea JA; Groeneveld P; Domchek SM; Armstrong K
    Cancer; 2013 Oct; 119(20):3596-603. PubMed ID: 23861169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim results.
    Sardanelli F; Podo F; D'Agnolo G; Verdecchia A; Santaquilani M; Musumeci R; Trecate G; Manoukian S; Morassut S; de Giacomi C; Federico M; Cortesi L; Corcione S; Cirillo S; Marra V; ; Cilotti A; Di Maggio C; Fausto A; Preda L; Zuiani C; Contegiacomo A; Orlacchio A; Calabrese M; Bonomo L; Di Cesare E; Tonutti M; Panizza P; Del Maschio A
    Radiology; 2007 Mar; 242(3):698-715. PubMed ID: 17244718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.
    Warner E; Plewes DB; Hill KA; Causer PA; Zubovits JT; Jong RA; Cutrara MR; DeBoer G; Yaffe MJ; Messner SJ; Meschino WS; Piron CA; Narod SA
    JAMA; 2004 Sep; 292(11):1317-25. PubMed ID: 15367553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Five screening-detected breast cancer cases in initially disease-free BRCA1 or BRCA2 mutation carriers.
    Shimada S; Yoshida R; Nakashima E; Kitagawa D; Gomi N; Horii R; Takeuchi S; Ashihara Y; Kita M; Akiyama F; Ohno S; Saito M; Arai M
    Breast Cancer; 2019 Nov; 26(6):846-851. PubMed ID: 30980249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA1/2 test results impact risk management attitudes, intentions, and uptake.
    O'Neill SC; Valdimarsdottir HB; Demarco TA; Peshkin BN; Graves KD; Brown K; Hurley KE; Isaacs C; Hecker S; Schwartz MD
    Breast Cancer Res Treat; 2010 Dec; 124(3):755-64. PubMed ID: 20383578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surveillance of Women with the BRCA1 or BRCA2 Mutation by Using Biannual Automated Breast US, MR Imaging, and Mammography.
    van Zelst JCM; Mus RDM; Woldringh G; Rutten MJCM; Bult P; Vreemann S; de Jong M; Karssemeijer N; Hoogerbrugge N; Mann RM
    Radiology; 2017 Nov; 285(2):376-388. PubMed ID: 28609204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study.
    Giannakeas V; Lubinski J; Gronwald J; Moller P; Armel S; Lynch HT; Foulkes WD; Kim-Sing C; Singer C; Neuhausen SL; Friedman E; Tung N; Senter L; Sun P; Narod SA
    Breast Cancer Res Treat; 2014 Aug; 147(1):113-8. PubMed ID: 25082516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison between CaGene 5.1 and 6.0 for BRCA1/2 mutation prediction: a retrospective study of 150 BRCA1/2 genetic tests in 517 families with breast/ovarian cancer.
    Antonucci I; Provenzano M; Sorino L; Balsamo M; Aceto GM; Battista P; Euhus D; Cianchetti E; Ballerini P; Natoli C; Palka G; Stuppia L
    J Hum Genet; 2017 Mar; 62(3):379-387. PubMed ID: 27928164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence to the breast cancer surveillance program for women at risk for familial breast and ovarian cancer versus overscreening: a monocenter study in Germany.
    Vetter L; Keller M; Bruckner T; Golatta M; Eismann S; Evers C; Dikow N; Sohn C; Heil J; Schott S
    Breast Cancer Res Treat; 2016 Apr; 156(2):289-99. PubMed ID: 26960712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer.
    Gamble C; Havrilesky LJ; Myers ER; Chino JP; Hollenbeck S; Plichta JK; Kelly Marcom P; Shelley Hwang E; Kauff ND; Greenup RA
    Ann Surg Oncol; 2017 Oct; 24(11):3116-3123. PubMed ID: 28699130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Family history predictors of BRCA1/BRCA2 mutation status among Tunisian breast/ovarian cancer families.
    Riahi A; Ghourabi ME; Fourati A; Chaabouni-Bouhamed H
    Breast Cancer; 2017 Mar; 24(2):238-244. PubMed ID: 27025497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer risk management practices of noncarriers within BRCA1/2 mutation positive families in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer.
    Dawson SJ; Price MA; Jenkins MA; McKinley JM; Butow PN; McLachlan SA; Lindeman GJ; Weideman P; Friedlander ML; Hopper JL; Phillips KA
    J Clin Oncol; 2008 Jan; 26(2):225-32. PubMed ID: 18040054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective blinded surveillance screening of Swedish women with increased hereditary risk of breast cancer.
    Liljegren A; von Wachenfeldt A; Azavedo E; Eloranta S; Grundström H; Ståhlbom AK; Sundbom A; Sundén P; Svane G; Ulitzsch D; Arver B
    Breast Cancer Res Treat; 2018 Apr; 168(3):655-666. PubMed ID: 29318406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
    Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.